argenx Announces Leadership Transition Marking Next Evolution of Growth

argenx SE, a global immunology company listed on Euronext and Nasdaq (ARGX), announced a strategic leadership transition as part of its preparation for the next phase of growth and execution of its long‑term Vision 2030 strategy. Effective pending shareholder approval at the Annual General Meeting on May 6, 2026, Chief Operating Officer Karen Massey will become Chief Executive Officer and Executive Director. Current CEO and co‑founder Tim Van Hauwermeiren will transition to the role of non‑Executive Director and Chairman of the Board of Directors, succeeding Peter Verhaeghe, who is retiring after serving on the board since 2008. Board Chairman Verhaeghe described the leadership change as timely and supportive of argenx’s future growth ambitions, expressing confidence in both Van Hauwermeiren’s and Massey’s leadership. Van Hauwermeiren highlighted Massey’s significant contributions over the past three years, including accelerating the launch of argenx’s key product VYVGART and strengthening the company’s commercial capabilities. As incoming CEO, Massey emphasized her commitment to leveraging argenx’s scientific foundation, culture, and teams to drive execution of Vision 2030 and build the biotech company of the future. Shareholders will vote on the proposed leadership and board transitions at the AGM. argenx continues to focus on translating immunology breakthroughs into novel antibody‑based medicines for patients with severe autoimmune diseases. #argenx #LeadershipTransition #BiotechGrowth #Vision2030 #SlimScan #GrowthStocks #CANSLIM